Skip to main content

Table 3 Changes in clinical laboratory data during the observation period

From: Switching from allopurinol to febuxostat: efficacy and tolerability in hemodialysis patients

   Follow-up period (months)
  Baseline 6 12 16 p*
Hemoglobin (g/dL) 10.9 ± 0.8 10.7 ± 0.9 10.3 ± 0.8 10.4 ± 0.7 0.23
Hematocrit (%) 32.6 ± 2.2 32.5 ± 2.8 30.9 ± 1.9 31.7 ± 2.6 0.47
Platelet count (×104 cells/mm3) 13.6 ± 5.7 14.7 ± 6.4 14.1 ± 5.5 13.8 ± 5.4 0.71
Blood urea nitrogen (mg/dL) 65.9 ± 13.6 66.0 ± 11.3 57.5 ± 9.3 66.3 ± 12.3 0.94
Serum creatinine (mg/dL) 13.1 ± 2.5 12.8 ± 2.0 12.3 ± 1.9 12.4 ± 2.1 0.14
Serum sodium (mEq/L) 137.1 ± 1.8 138.1 ± 2.0 138.8 ± 1.4 138.2 ± 2.3 0.13
Serum potassium (mEq/L) 5.6 ± 0.5 5.2 ± 0.5 5.1 ± 0.5 5.7 ± 0.5 0.40
Serum chloride (mEq/L) 107.6 ± 2.1 106.8 ± 2.9 109.1 ± 2.2 108.4 ± 1.8 0.35
Serum calcium (mEq/L) 8.6 ± 0.3 8.5 ± 0.5 8.6 ± 0.4 8.6 ± 0.6 0.81
Serum inorganic phosphorus (mEq/L) 4.5 ± 0.6 4.9 ± 0.9 4.3 ± 0.8 5.0 ± 1.0 0.27
Aspartate transaminase (U/L) 10.2 ± 3.2 11.3 ± 4.4 9.2 ± 3.2 12.8 ± 5.4 0.21
Alanine aminotransferase (U/L) 10.4 ± 3.0 10.2 ± 3.3 9.8 ± 4.5 11.7 ± 4.7 0.54
Alkaline phosphatase (U/L) 196.6 ± 53.6 217.6 ± 82.6 198.0 ± 48.0 222.3 ± 67.1 0.09
Lactate dehydrogenase (U/L) 155.2 ± 27.1 157.6 ± 29.5 165.8 ± 23.3 165.3 ± 23.1 0.30
Total protein (g/dL) 5.9 ± 0.2 6.0 ± 0.4 5.9 ± 0.4 5.9 ± 0.3 0.63
  1. Values are means ± standard deviation
  2. *p < 0.05 between baseline and 16 months, paired t-test